Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants.

Moss JL, Murphy J, Filiaci VL, Wenzel LB, Minasian L, Temkin SM.

Support Care Cancer. 2018 Jul 12. doi: 10.1007/s00520-018-4340-9. [Epub ahead of print]

PMID:
30003341
2.

Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation.

Bergstrom JE, Scott ME, Alimi Y, Yen TT, Hobson D, Machado KK, Tanner EJ 3rd, Fader AN, Temkin SM, Wethington S, Levinson K, Sokolinsky S, Lau B, Stone RL.

Gynecol Oncol. 2018 Jun;149(3):554-559. doi: 10.1016/j.ygyno.2018.04.003. Epub 2018 Apr 13.

PMID:
29661495
3.

A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.

Temkin SM, Rimel BJ, Bruegl AS, Gunderson CC, Beavis AL, Doll KM.

Gynecol Oncol. 2018 Apr;149(1):70-77. doi: 10.1016/j.ygyno.2017.11.013. Review.

PMID:
29605053
4.

Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States.

Temkin SM, Kohn EC, Penberthy L, Cronin KA, Rubinsak L, Dickie LA, Minasian L, Noone AM.

Cancer Causes Control. 2018 May;29(4-5):427-433. doi: 10.1007/s10552-018-1018-z. Epub 2018 Mar 1.

PMID:
29497884
5.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, Mutch D, Temkin SM, Lynn J, Kohn EC.

Gynecol Oncol. 2018 Feb 22. pii: S0090-8258(18)30124-0. doi: 10.1016/j.ygyno.2018.02.005. [Epub ahead of print] Review.

PMID:
29477660
6.

Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.

Temkin SM, Miller EA, Samimi G, Berg CD, Pinsky P, Minasian L.

Eur J Cancer. 2017 Dec;87:182-188. doi: 10.1016/j.ejca.2017.10.015. Epub 2017 Nov 21.

PMID:
29156299
7.

Editorial: Cancer Care Delivery and Women's Health: Beyond the Patient and Provider Relationship.

Temkin SM.

Front Oncol. 2017 Sep 14;7:213. doi: 10.3389/fonc.2017.00213. eCollection 2017. No abstract available.

8.

Ovarian Cancer Prevention in High-risk Women.

Temkin SM, Bergstrom J, Samimi G, Minasian L.

Clin Obstet Gynecol. 2017 Dec;60(4):738-757. doi: 10.1097/GRF.0000000000000318. Review.

PMID:
28957949
9.

Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.

Lippitt MH, Fairbairn MG, Matsuno R, Stone RL, Tanner EJ 3rd, Wick EC, Angarita AC, Roche KL, Levinson KL, Bergstrom JE, Sinno AK, Curless MS, Wethington S, Temkin SM, Efron J, Hobson D, Fader AN.

Obstet Gynecol. 2017 Oct;130(4):756-764. doi: 10.1097/AOG.0000000000002213.

PMID:
28885412
10.

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future.

Fields EC, McGuire WP, Lin L, Temkin SM.

Front Oncol. 2017 Aug 21;7:177. doi: 10.3389/fonc.2017.00177. eCollection 2017. Review.

11.

Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.

Sinno AK, Li X, Thompson RE, Tanner EJ 3rd, Levinson KL, Stone RL, Temkin SM, Fader AN, Chi DS, Long Roche K.

Gynecol Oncol. 2017 Jun;145(3):493-499. doi: 10.1016/j.ygyno.2017.03.020. Epub 2017 Mar 30.

12.

The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.

Cohn DE, Ko E, Meyer LA, Wright JD, Temkin SM, Foote J, Jones NL, Havrilesky LJ.

Gynecol Oncol. 2017 Apr;145(1):185-191. doi: 10.1016/j.ygyno.2017.02.024. Epub 2017 Mar 1. Review. No abstract available.

13.

Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer.

Sinno AK, Peijnenburg E, Fader AN, Temkin SM, Stone R, Levinson K, Murdock T, Tanner EJ.

Gynecol Oncol. 2016 Nov;143(2):281-286. doi: 10.1016/j.ygyno.2016.08.323. Epub 2016 Aug 24.

PMID:
27568279
14.

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.

Fader AN, Java J, Tenney M, Ricci S, Gunderson CC, Temkin SM, Spirtos N, Kushnir CL, Pearl ML, Zivanovic O, Tewari KS, O'Malley D, Hartenbach EM, Hamilton CA, Gould NS, Mannel RS, Rodgers W, Walker JL.

Gynecol Oncol. 2016 Dec;143(3):460-465. doi: 10.1016/j.ygyno.2016.10.016. Epub 2016 Oct 12.

15.

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.

Mishkin G, Minasian LM, Kohn EC, Noone AM, Temkin SM.

Gynecol Oncol. 2016 Dec;143(3):611-616. doi: 10.1016/j.ygyno.2016.09.026. Epub 2016 Sep 30.

PMID:
27697287
16.

Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.

Wilbur MB, Mannschreck DB, Angarita AM, Matsuno RK, Tanner EJ, Stone RL, Levinson KL, Temkin SM, Makary MA, Leung CA, Deutschendorf A, Pronovost PJ, Brown A, Fader AN.

Gynecol Oncol. 2016 Dec;143(3):604-610. doi: 10.1016/j.ygyno.2016.09.020. Epub 2016 Sep 21.

PMID:
27665313
17.

The Use of "Optimal Cytoreduction" Nomenclature in Ovarian Cancer Literature: Can We Move Toward a More Optimal Classification System?

Angarita AM, Stone R, Temkin SM, Levinson K, Fader AN, Tanner EJ.

Int J Gynecol Cancer. 2016 Oct;26(8):1421-7. doi: 10.1097/IGC.0000000000000796.

PMID:
27575626
18.

Disparities in Surgical Care Among Women With Endometrial Cancer.

Mannschreck D, Matsuno RK, Moriarty JP, Borah BJ, Dowdy SC, Tanner EJ 3rd, Makary MA, Stone RL, Levinson KL, Temkin SM, Fader AN.

Obstet Gynecol. 2016 Sep;128(3):526-34. doi: 10.1097/AOG.0000000000001567.

PMID:
27500330
19.

Primary Placement of Incisional Negative Pressure Wound Therapy at Time of Laparotomy for Gynecologic Malignancies.

Lynam S, Mark KS, Temkin SM.

Int J Gynecol Cancer. 2016 Oct;26(8):1525-9. doi: 10.1097/IGC.0000000000000792.

PMID:
27488215
20.

Endometrial cancer: Not your grandmother's cancer.

McAlpine JN, Temkin SM, Mackay HJ.

Cancer. 2016 Sep 15;122(18):2787-98. doi: 10.1002/cncr.30094. Epub 2016 Jun 16. Review.

21.

Reducing Overtreatment in Gynecologic Oncology: The Case for Less in Endometrial and Ovarian Cancer.

Temkin SM, Tanner EJ, Dewdney SB, Minasian LM.

Front Oncol. 2016 May 9;6:118. doi: 10.3389/fonc.2016.00118. eCollection 2016. Review.

22.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.

Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24. Review.

23.

The End of the Hysterectomy Epidemic and Endometrial Cancer Incidence: What Are the Unintended Consequences of Declining Hysterectomy Rates?

Temkin SM, Minasian L, Noone AM.

Front Oncol. 2016 Apr 14;6:89. doi: 10.3389/fonc.2016.00089. eCollection 2016. Review.

24.

VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.

Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ.

Clin Cancer Res. 2016 Aug 15;22(16):4249-58. doi: 10.1158/1078-0432.CCR-15-2518. Epub 2016 Apr 13.

25.

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years.

Gibson SJ, Fleming GF, Temkin SM, Chase DM.

Front Oncol. 2016 Mar 24;6:63. doi: 10.3389/fonc.2016.00063. eCollection 2016. Review.

26.

National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons.

Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL.

Support Care Cancer. 2016 Mar;24(3):1439-47. doi: 10.1007/s00520-015-3063-4. Epub 2015 Dec 19. Review.

27.

Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease.

Wright JD, Cui RR, Wang A, Chen L, Tergas AI, Burke WM, Ananth CV, Hou JY, Neugut AI, Temkin SM, Wang YC, Hershman DL.

J Natl Cancer Inst. 2015 Oct 8;107(11). pii: djv251. doi: 10.1093/jnci/djv251. Print 2015 Nov.

28.

Trends in Relative Survival for Ovarian Cancer From 1975-2011.

Temkin SM, Terplan M.

Obstet Gynecol. 2015 Oct;126(4):898. doi: 10.1097/AOG.0000000000001073. No abstract available.

PMID:
26393445
29.

Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers.

Temkin SM, Seibel NL.

Cancer. 2015 Oct 1;121(19):3395-402. doi: 10.1002/cncr.29515. Epub 2015 Jun 25. Review.

30.

"Less is more:" The harms of overtreatment in early ovarian cancer.

Temkin SM.

Gynecol Oncol. 2015 May;137(2):191-2. doi: 10.1016/j.ygyno.2015.04.007. No abstract available.

PMID:
25953509
31.

Geographic disparities amongst patients with gynecologic malignancies at an urban NCI-designated cancer center.

Temkin SM, Fleming SA, Amrane S, Schluterman N, Terplan M.

Gynecol Oncol. 2015 Jun;137(3):497-502. doi: 10.1016/j.ygyno.2015.03.010. Epub 2015 Mar 17.

PMID:
25795262
32.

Black and white women in Maryland receive different treatment for cervical cancer.

Fleming S, Schluterman NH, Tracy JK, Temkin SM.

PLoS One. 2014 Aug 14;9(8):e104344. doi: 10.1371/journal.pone.0104344. eCollection 2014.

33.

Breast self-awareness: the evidence behind the euphemism.

Mark K, Temkin SM, Terplan M.

Obstet Gynecol. 2014 Apr;123(4):734-6. doi: 10.1097/AOG.0000000000000139.

PMID:
24785598
34.

Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.

Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM.

Gynecol Oncol. 2013 Apr;129(1):120-3. doi: 10.1016/j.ygyno.2012.12.006. Epub 2012 Dec 10.

35.

Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.

Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD.

Gynecol Oncol. 2012 Nov;127(2):316-20. doi: 10.1016/j.ygyno.2012.07.105. Epub 2012 Jul 24.

PMID:
22835717
36.

Have racial disparities in ovarian cancer increased over time? An analysis of SEER data.

Terplan M, Schluterman N, McNamara EJ, Tracy JK, Temkin SM.

Gynecol Oncol. 2012 Apr;125(1):19-24. doi: 10.1016/j.ygyno.2011.11.025. Epub 2011 Nov 21.

PMID:
22108636
37.

Assessing gynecologic and breast cancer survivors' sexual health care needs.

Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST.

Cancer. 2011 Jun 15;117(12):2643-51. doi: 10.1002/cncr.25832. Epub 2010 Dec 23.

39.

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.

Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM.

Gynecol Oncol. 2011 Apr;121(1):218-23. doi: 10.1016/j.ygyno.2010.11.031. Epub 2010 Dec 17.

PMID:
21168200
40.

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

Temkin SM, Yamada SD, Fleming GF.

Gynecol Oncol. 2010 Jun;117(3):473-6. doi: 10.1016/j.ygyno.2010.02.022. Epub 2010 Mar 28.

PMID:
20347480
41.

Subcutaneous methylnaltrexone to restore postoperative bowel function in a long-term opiate user.

Ladanyi A, Temkin SM, Moss J.

Int J Gynecol Cancer. 2010 Feb;20(2):308-10. doi: 10.1111/IGC.0b013e3181cd1828.

PMID:
20134275
42.

Race in ovarian cancer treatment and survival: a systematic review with meta-analysis.

Terplan M, Smith EJ, Temkin SM.

Cancer Causes Control. 2009 Sep;20(7):1139-50. doi: 10.1007/s10552-009-9322-2. Epub 2009 Mar 14. Review.

PMID:
19288217
43.

Current treatment of metastatic endometrial cancer.

Temkin SM, Fleming G.

Cancer Control. 2009 Jan;16(1):38-45. Review.

PMID:
19078928
44.

Dysplastic endocervical curettings: a predictor of cervical squamous cell carcinoma.

Temkin SM, Hellmann M, Lee YC, Abulafia O.

Am J Obstet Gynecol. 2007 May;196(5):469.e1-4.

PMID:
17466706
45.

Surgical resection of vulvar metastases of endometrial cancer: a presentation of two cases.

Temkin SM, Hellman M, Lee YC, Abulafia O.

J Low Genit Tract Dis. 2007 Apr;11(2):118-21.

PMID:
17415118
46.

Primary spindle cell sarcoma of the vagina treated with neoadjuvant radiation and pelvic exenteration.

Temkin SM, Hellmann M, Lee YC, Abulafia O.

J Low Genit Tract Dis. 2007 Apr;11(2):105-7.

PMID:
17415115
47.

Early-stage carcinosarcoma of the uterus: the significance of lymph node count.

Temkin SM, Hellmann M, Lee YC, Abulafia O.

Int J Gynecol Cancer. 2007 Jan-Feb;17(1):215-9.

PMID:
17291256
48.

Is body mass index an independent risk factor of survival among patients with endometrial cancer?

Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O.

Am J Clin Oncol. 2007 Feb;30(1):8-14.

PMID:
17278888
49.

Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation.

Temkin SM, Hellmann M, Serur E, Lee YC, Abulafia O.

Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1855-61.

PMID:
17009982
50.

Thrombotic thrombocytopenic purpura in a patient with acquired immunodeficiency syndrome at 28 weeks gestation.

Sherer DM, Sanmugarajah J, Dalloul M, Temkin SM, Thanus J, Abulafia O.

Am J Perinatol. 2005 May;22(4):223-5.

PMID:
15906217

Supplemental Content

Loading ...
Support Center